The Europe pharmaceutical packaging market is projected to increase from USD 49.24 billion in 2025 to approximately USD 95.78 billion by 2030, fueled by increasing demand for safe, compliant, and patient-centered packaging solutions. Pharmaceutical packaging applies to primary formats (e.g., vials, syringes, blister packs, bottles, and closures), as well as secondary and tertiary formats (e.g., cartons, labels, and tamper-evident systems). These formats are critical to drug stability, patient safety, and compliance in several therapeutic categories, such as biologics, vaccines, and specialty medicines. The main drivers of this growth are increasing incidences of chronic diseases, the expansion of injectable drug delivery, and increasing demand for smart and sustainable pack formats that comply with global regulations. 

The Europe pharmaceutical packaging industry is undergoing a transformation toward sustainability, digitalization, and innovation in drug delivery systems. Tighter environmental regulations and consumer

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34761714

preferences are spurring companies to embrace recyclable plastics, bio-based polymers, lighter-weight glass, and circular economy approaches to help limit the impact on the planet. Concomitantly, digital offerings, such as track-and-trace labels, anti-counterfeit packaging, and smart blisters, are shifting the industry's paradigm to enhance patient adherence and add transparency and trust across the supply chain. New developments in bioprocessing include alternatives such as barrier materials for biologics, sterile prefillable injectables, and child-resistant closures to enhance medication safety. These innovations have increased the tempo, driven by ever-increasing investments in R&D. The forces of compliance, sustainability, and performance are expected to bring a paradigm shift to the pharmaceutical packaging industry. 

In the raw material segment, plastics held the largest market share in 2024. Plastics such as polyethylene (PE), polypropylene (PP), polyethylene terephthalate (PET), and polyvinyl chloride (PVC) provide lightweight, durable, and flexible designs. All these plastic materials are used in bottles, blister packs, closures, and flexible films, all of which help keep products viable and portable while remaining economically acceptable. With some innovation, materials have evolved to the point of creating plastics that offer greater barrier performance and recyclability, addressing a growing regulatory and consumer focus on sustainable packaging alternatives. Their versatility and compatibility with a wide range of pharmaceutical formulations reinforce their dominance across the global market. 

On the basis of type, plastic bottles accounted for the largest share of the European pharmaceutical packaging market in the forecast period. In view of the protective qualities, ease of access, and widespread availability of such products, they have varying shapes and sizes, plastic bottles are used worldwide for packaging a diversified range of liquid products, tablets, and capsules. Plastic bottles can be packaged with child-resistant, tamper-evident caps to ensure patient safety and comply with regulatory directives. Latest developments in light plastic bottles, barrier coatings, and plastic with recycled content further improved their use and acceptance. The low cost, availability, and demand for over-the-counter (OTC) medicines and prescription drugs have ensured their standardization across the pharmaceutical packaging industry. 

In terms of drug delivery, injectables held the largest market share in the European pharmaceutical packaging market in 2024. Prefilled syringes, vials, ampoules, and cartridges are at the forefront of injectable drug packaging due to their ability to deliver accurate dosing, sterility, and patient protection. Packaging formats have been widely used for biologics, vaccines, and chronic diseases. This is because a high degree of accuracy is required, along with the need to prevent contamination. Moreover, the rise in biologics and biosimilars, combined with the growing burden of chronic diseases (e.g., cancer, diabetes, and autoimmune illnesses), is driving demand for advanced injectable packaging. Apart from the importance of prefilled syringes, vials, or cartridges, manufacturers are also working on other innovations, including safe-engineered packaging, auto-injectors, and eco-friendly packaging formats, resulting in improved patient convenience, reduced risk factors related to needlestick injury, and mitigation of regulatory issues.

Get a Sample Copy of This Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=34761714

During the forecast period, Russia is expected to remain the largest market for European pharmaceutical packaging, supported by its well-established healthcare infrastructure, significant pharmaceutical production base, and high healthcare spending. Demand in the region is primarily driven by the US, which features a large and growing geriatric population with a growing prevalence of chronic and age-related diseases, such as Alzheimer's disease, diabetes, and cardiovascular disease. The growing geriatric population is driving demand for patient-friendly, safe, and easy-to-use packaging formats, such as blister packaging, vials, syringes, and child-resistant bottles. Meanwhile, Russia has increasingly focused on biologics and specialty drugs, thereby driving advanced primary packaging demand, especially for prefillable syringes and sterile barrier systems, which help the region maintain strong market dominance. 

The pharmaceutical packaging segment in Europe is well developed, driven by a strong manufacturing base, advanced materials capabilities, and the pharmaceutical and biotech sector, comprising Germany, Switzerland, France, Italy, and the Nordic countries. An important factor in this growth is the strict maintenance of government regulations. The Europe pharmaceutical industry complies with the strict regulations issued by the European Medicines Agency (EMA), EU GMP, and other regulatory bodies such as REACH, MDR, and the EU Green Deal. The pharmaceutical packaging needs to comply with strict requirements in terms of safety, sterility, and biocompatibility and patient-friendly designs, and this has led to the rise of senior-friendly, tamper-proof, and child-resistant packages in glass and plastic.

Amcor plc is a leading packaging company for food, beverage, pharmaceutical, medical, home & personal care, and other products. It is primarily involved in the manufacturing and marketing of flexible packaging, rigid containers, and specialty cartons and closures by using raw materials such as polymers, aluminum foils, and fibers. Amcor PLO operates a substantial global network of manufacturing and support facilities across its two main segments: Flexibles and Rigid Packaging. With 36 countries housing 160 major operations, the Flexibles segment is made up of 111 owned and 49 leased (or rented) from outside sources. Each of those properties typically has lease terms initially ranging from 2 to 36 years and often includes one or more renewal options. In comparison, the Rigid Packaging segment includes 52 significant facilities across 11 countries, with a smaller proportion owned directly by the company-12 facilities-while the remaining 40 are leased. Lease periods for the Rigid Packaging facilities are typically between 2-20 years, with many containing renewal options, which further shows the Flexibles segment has the largest worldwide presence, and also holds a much larger percentage of its property in owned facilities than does the Rigid Packaging segment, which is primarily dependent upon leasing. Amcor plc has a wide range of healthcare packaging for oral, dermal, medical devices, hospital packaging, ophthalmic & vision care, pulmonary, intravenous fluid, and injectables. It performs its operations through subsidiaries in the EMEA (Europe, the Middle East, and Africa), the Americas, and Asia Pacific. The company operates through 212 production sites in more than 40 countries.

Gerresheimer AG is a well-recognized leader in the pharma and healthcare packaging and systems in Europe. With production sites in Europe, North and South America, and Asia, Gerresheimer develops and produces primary packaging solutions from glass and plastic for medicines, diagnostics, and cosmetics. Gerresheimer has three operating divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies, with pharmaceutical packaging existing mainly in the two former business units. Gerresheimer has a worldwide manufacturing presence, including 36 production sites in 15 countries-Germany, Belgium, France, Spain, Denmark, Switzerland, Poland, the Czech Republic, North Macedonia, Mexico, Brazil, the US, India, China, and Singapore-to maintain the company close to the major pharma hubs and customers. Offering a broad product range, from vials, ampuls, and syringes to complex drug-delivery devices.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=34761714

Schott AG manufactures high-tech materials for specialty glasses. The company operates as a subsidiary of Carl-Zeiss-Stiftung (Germany). It operates through precision materials, optical industries, home appliances, and trade & others. The packaging business is conducted through its precision materials business division. Schott AG serves numerous industries, including healthcare, home appliances & living, consumer electronics, semiconductors & datacom, optics, industry & energy, automotive, and astronomy & aerospace. Schott established its subsidiary, Schott Pharma, to advance its growth strategy for its pharma business, particularly in drug containment and delivery solutions. Schott Pharma’s product line includes drug containment options to drug delivery systems, such as pharmaceutical syringes, cartridges, vials, and ampoules, with over 13 billion drug containers produced yearly. Schott AG offers glass tubing and primary packaging, including syringes, vials, ampoules, and cartridges for the pharmaceutical industry. Schott has manufacturing sites and sales offices in 34 countries and 600 production sites in 13 countries. The company has 17,400 employees worldwide.

Nolato AB is a Swedish, publicly listed polymer solutions company that supplies the pharmaceutical and medical technology industries with high-quality primary plastic packaging. Within its Medical Solutions business, Nolato designs and manufactures packaging, including bottles, containers, caps, and closures, with strong expertise in child-resistant and tamper-evident systems and in low-moisture-permeation designs suited for sensitive drug formulations. Through specialist units such as Nolato Cerbo (Sweden) and Nolato Jaycare (UK), the company combines advanced injection and injection-blow molding, cleanroom manufacturing, and GMP-aligned traceability to support both prescription and over-the-counter medicines. Nolato’s pharmaceutical packaging portfolio is built around patient safety, regulatory compliance, and design-for-manufacture, with increasing integration of sustainability-driven material choices and lifecycle considerations for global pharmaceutical customers.

Smurfit WestRock, headquartered in Ireland, is a leading global player in paper-based packaging following its merger with Smurfit Kappa. It supplies a full range of secondary pharmaceutical packaging and medication management solutions not only to Europe but also worldwide. The health and pharma division of the company is capable of offering a wide range of products, such as folding cartons, printed cartons, labels, leaflets, tamper-evident and child-resistant packs, as well as clinical, trial, and patient adherence packaging systems that are designed to meet the most stringent regulatory and patient use requirements. Smurfit Westrock assists pharmaceutical companies by providing design, printing, security features, and supply chain improvements, thus allowing brand communication, compliance, and drug protection at every stage of the medicine lifecycle. Besides that, the company is very much into using renewable and recyclable materials and has, therefore, financially backed the construction of separate, GMP-compliant clinical and adherence packaging facilities in Europe. This is a clear indication of how Smurfit Westrock is working to cement its position as a full-service partner to the regulated pharmaceutical packaging industry.